Publication: No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting
No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting
Date
Date
Date
Citations
Jacob, F., Meier, M., Caduff, R., Goldstein, D., Pochechueva, T., Hacker, N., Fink, D., & Heinzelmann-Schwarz, V. (2011). No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecologic Oncology, 121(3), 487–491. https://doi.org/10.1016/j.ygyno.2011.02.022
Abstract
Abstract
Abstract
OBJECTIVE: About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity for early cancers, many of which are potentially curable. METHODS: We compared the new commercially available tumor marker HE4 with CA125 individually, in combination, within the risk of malignancy index (RMI) and the newly defined risk of malignancy algorithm (ROMA). Our prospectively-collected cohort of 160 patients co
Additional indexing
Creators (Authors)
Journal/Series Title
Journal/Series Title
Journal/Series Title
Volume
Volume
Volume
Number
Number
Number
Page Range
Page Range
Page Range
Page end
Page end
Page end
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Citations
Jacob, F., Meier, M., Caduff, R., Goldstein, D., Pochechueva, T., Hacker, N., Fink, D., & Heinzelmann-Schwarz, V. (2011). No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecologic Oncology, 121(3), 487–491. https://doi.org/10.1016/j.ygyno.2011.02.022